GS
MIRA icon

GTS Securities’s MIRA Pharmaceuticals MIRA Stock Holding History

GTS Securities’s Portfolio MIRA Stock Details MIRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-37,852
Closed -$39.7K – 4211
2023
Q4 		$39.7K Buy
+37,852
New +$96.2K ﹤0.01% 3854

Other funds holding MIRA

CSI
Cross Staff Investments Pittsford, New York $197M AUM 14.68% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FAB
First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CSPIA
Cary Street Partners Investment Advisory Richmond, Virginia $494M AUM 27.12% 1-Year Est. Return

GTS Securities's MIRA Position: Q1 2024 in Review

GTS Securities sold out of MIRA Pharmaceuticals (MIRA) in Q1 2024, closing a stake of 37,852 shares — an estimated $39.7K sold.

GTS Securities first reported a position in MIRA in Q4 2023 and held it in 1 quarter. The position peaked at $39.7K in Q4 2023. 11 funds tracked by Wall St. Rank hold MIRA as of Q1 2024.

  • GTS Securities reported no remaining MIRA Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • GTS Securities sold 37,852 MIRA Pharmaceuticals shares in Q1 2024, an estimated $39.7K.
  • GTS Securities first reported a position in MIRA Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • GTS Securities's MIRA Pharmaceuticals position peaked at $39.7K in Q4 2023.
  • 11 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q1 2024.

Based on GTS Securities's 13F filing for Q1 2024, filed 15 May 2024.